Revolution Medicines and Summit Therapeutics entered into a clinical collaboration in multiple solid-tumor settings to evaluate their respective treatments in combination with each other. Redwood City ...

Royalty Pharma will pay up to $2 billion to Revolution Medicines to support the development and sales of an experimental drug ...

Royalty Pharma Plc. (RPRX) on Tuesday announced a $2 billion funding arrangement with Revolution Medicines (RVMD), aimed at ...

Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology firm focused on targeted treatments for RAS-driven ...

A total of $1.25 billion of the money pledged by Royalty has been agreed in exchange for tiered royalties on net sales of ...

Revolution Medicines projected its cash and equivalents of $2.1 billion would last into the second half of 2027. With new ...

Revolution Medicines, Inc. Transaction on Track to Close in November 2023. REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a ...

Revolution Medicines Expects to Conduct Late-Stage Development of RAS(ON) Inhibitor Drug Candidate Pipeline Supported by Fortified Balance Sheet Agreement is the Result of a Rigorous Process ...

Revolution Medicines raised $238 million via its 2020 IPO, and 4 years later has grown its share price by ~30%, bringing its market cap valuation to $6 billion.

Up to $1.25 billion ($250 million upfront) of synthetic royalty funding and up to $750 million in secured debt ; Innovative partnership enables Revolution Medicines to retain control over pipeline ...

Despite a robust cash position, Revolution Medicines' high burn rate and lofty valuation increase risk and sensitivity to ...

Revolution Medicines, Inc. announced that the U.S. FDA has granted Breakthrough Therapy Designation to daraxonrasib, a multi-selective inhibitor targeting KRAS G12 mutations in patients with ...